UCB S.A. has presented another set of data, arguably the most significant set yet, on bimekizumab which demonstrated that the investigational interleukin-17A and IL-17F inhibitor proved more effective than Novartis AG's blockbuster IL-17A inhibitor Cosentyx in achieving complete skin clearance in psoriasis patients.
UCB Is RADIANT As Bimekizumab Beats Cosentyx For Psoriasis
IL-17A And IL-17F Inhibitor Just Filed In US And Europe
The psoriasis market is crowded and fiercely competitive but the Belgian group's bimekizumab has bested Novartis's interleukin-17A behemoth Cosentyx in a head-to-head study. Whether UCB goes it alone or signs up a large partner with a large marketing budget remains to be seen.
